Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic, clinical, and laboratory data of the methotrexate study cohort

From: Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue

Characteristics of cohort Value
Number of patients 13
Median age (range), years 56 (32-78)
Number of males/females 4/9
Median interval from diagnosis (range), days 7 (1-25)
Median duration of symptoms (range), months 6.5 (2-12)
ACPA-positive patients, number (percentage) 6 (46)
Rheumatoid factor-positive patients, number (percentage) 9 (69)
Number of patients taking oral corticosteroids 2
Number of patients taking NSAIDs 10
Median duration between biopsies (range), days 58 (45-70)
Number of patients presenting erosions (percentage)  
   At baseline 2 (15)
   After 1 year 7 (53)
Mean DAS28 (minimum, maximum)  
   At baseline 5.7 (3.9, 6.7)
   After 3 months 3.8 (1.8, 5.8)
  1. ACPA, anti-cyclic citrullinated peptide antibody; DAS28, Disease Activity Score in 28 joints; NSAID, non-steroidal anti-inflammatory drug.